Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 158-165 , March 2008

Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma

  • Ismail T. Koksal, M.D.

      Affiliations

    • Human Gene Therapy Unit and the Department of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey
    • Department of Urology, Akdeniz University, Faculty of Medicine, Antalya, Turkey
    • ,
  • Ahter D. Sanlioglu, Ph.D.

      Affiliations

    • Human Gene Therapy Unit and the Department of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey
    • ,
  • Bahri Karacay, Ph.D.

      Affiliations

    • Departments of Pediatrics-Urology and the Center for Gene Therapy at the University of Iowa, Iowa City 52242, IA, USA
    • ,
  • Thomas S. Griffith, Ph.D.

      Affiliations

    • Departments of Pediatrics-Urology and the Center for Gene Therapy at the University of Iowa, Iowa City 52242, IA, USA
    • ,
  • Salih Sanlioglu, V.M.D., Ph.D.

      Affiliations

    • Human Gene Therapy Unit and the Department of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90-242-249-6157; fax: +90-242-227-4482.

Received 17 October 2006 ,Revised 16 January 2007 ,Accepted 18 January 2007.

References 

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843–848
  3. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110–114
  4. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161
  5. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–916
  6. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143:747–752
  7. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50:125–128
  8. D’Amico AV, Renshaw AA, Arsenault L, et al. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: Potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys. 1999;45:841–846
  9. Koksal IT, Ozcan F, Kadioglu TC, et al. Discrepancy between Gleason scores of biopsy and radical prostatectomy specimens. Eur Urol. 2000;37:670–674
  10. Koksal IT, Yasar D, Dirice E, et al. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol Int. 2005;75:102–106
  11. Koksal IT, Dirice E, Yasar D, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol. 2004;22:307–312
  12. Sanlioglu AD, Aydin C, Bozcuk H, et al. Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer. 2004;44:199–211
  13. Griffith TS, Lynch DH. TRAIL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559–563
  14. Griffith TS, Fialkov JM, Scott DL, et al. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 2002;62:3093–3099
  15. Terzioglu E, Biskin A, Sanlioglu AD, et al. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;Feb 29: doi:10.1093/rheumatology/kel448 [Epub ahead of print]
  16. Sanlioglu AD, Dirice E, Aydin C, et al. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005;5:54
  17. Sanlioglu AD, Koksal IT, Karacay B, et al. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther. 2006;13:21–31
  18. Aydin C, Sanlioglu AD, Karacay B, et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther. 2007;18:39–50
  19. Sanlioglu AD, Koksal IT, Ciftcioglu A, et al. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol. 2007;177:359–364
  20. Sobin LH, Wittekind CH. TNM classification of malignant tumors. 6th ed.. New York (NY): Wiley-Liss; 2002;
  21. Amling CL, Bergstralh EJ, Blute ML, et al. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?. J Urol. 2001;165:1146–1151
  22. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol. 1994;10:60–72
  23. Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999;161:1238–1243
  24. Rietbergen JB, Hoedemaeker RF, Kruger AE, et al. The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population based screening study. J Urol. 1999;161:1192–1198
  25. Freedland SJ, Mangold LA, Walsh PC, et al. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol. 2005;174:1276–1281
  26. Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer (A prospective, population-based study in Sweden). JAMA. 1997;277:467–471
  27. Koksal IT, Ozcan F, Kilicaslan I, et al. Expression of E-cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: Correlation with pathological features. Pathology. 2002;34:233–238
  28. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71:3582–3593
  29. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther. 2001;4:257–266
  30. Griffith TS, Anderson RD, Davidson BL, et al. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 2000;165:2886–2894

☆ This study was supported by Akdeniz University Scientific Research Project Administration Division Grant.

PII: S1078-1439(07)00022-1

doi: 10.1016/j.urolonc.2007.01.022

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 158-165 , March 2008

Article Tools

* Image Usage & Resolution